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the two scales on different patients can be compared or integrated across stud-
ies. Methods: Data were taken from the 2011 and 2012 US National Health and 
Wellness Survey (NHWS). The NHWS is a large cross-sectional survey representative 
of the total adult population in several major markets; current analyses were limited 
to the US (n~75,000/year). Respondents self-reported physician diagnosis of various 
health conditions, including 9,633 who reported a diagnosis of IBS. Adherence was 
measured with MMAS-4 in 2011 and MMAS-8 in 2012. The two adherence scales 
were evaluated by comparing the frequency distributions of the MMAS scores in the 
two scales, Cronbach’s alpha and inter-item correlations, and the creation of a new 
4-item scale including the questions in MMAS-8 that best matched the questions 
in MMAS-4. Results: In IBS patients, both MMAS-4 and -8 scores are Poisson-like 
distributed, with median at zero (high adherence). Chronbach’s alpha was 0.64 for 
MMAS-4 and 0.70 for MMAS-8, while average item-test correlations were 0.70 and 
0.59, respectively. The reduced 4-item scale created out of MMAS-8 is also Poisson-
like distributed, Cronbach’s alpha was 0.67 and the average item-test correlation was 
0.71. ConClusions: Data obtained with the two MMAS show similar qualitative 
and quantitative characteristics, suggesting that it may be appropriate to integrate 
data sources using the two different versions, particularly when the responses to 
the subset of 4 MMAS-8 items are available. Future research should confirm that 
the scales can be integrated in different therapeutic areas.
PRM166
Using Feedback FRoM Patients in deteRMining sUitability oF the 
PeRceived deFicits QUestionnaiRe (PdQ) and the ResoURce Utilization 
in deMentia-lite (RUd-lite) FoR Use in clinical tRials in PRodRoMal 
alzheiMeR’s disease
Lenderking W.R.1, Steenrod A.2, Rudell K.3, Klapper S.2, Howard K.2, Gaudig M.4
1Evidera, Lexington, MA, USA, 2Evidera, Bethesda, MD, USA, 3Pfizer Limited, Tadworth, UK, 
4Janssen Alzheimer Immunotherapy, Neuss, Germany
objeCtives: Many instruments used to assess outcomes of treatment for Alzheimer’s 
disease (AD) have no published evidence for their content validity in mild cognitive 
impairment (MCI) or prodromal AD (pAD). The objective of this project was to evalu-
ate the content validity of AD patient reported outcome (PRO) instruments in this 
population. Methods: Two waves of interviews were conducted: First, 11 patients 
with MCI and their informants/ (carers) evaluated several AD PROs (Alzheimer’s 
Disease Medication Administration Questionnaire (ADMAQ), Abbreviated Resource 
Utilization in Dementia-Lite (RUD-Lite), Perceived Deficits Questionnaire (PDQ), and 
Abbreviated Dependence Scale (AB DS); Second, 8 patients with pAD reviewed the 
modified PDQ, and their carers reviewed the RUD Lite. Interviews were transcribed 
and analysed. Results: Results of Wave 1 identified the PDQ and the RUD-Lite as 
the most promising measures for this cohort. Some minor modifications were sug-
gested for the PDQ, and a separate section was added to the RUD-Lite. Results of Wave 
2 showed pAD carers viewed the content of the RUD- Lite as less relevant because 
the patients are not functionally restricted enough to utilize resources at this early 
stage of the disease, although the newly added domain for the pAD population was 
understood and applicable. The modified PDQ was more acceptable to pAD patients 
than the original version. ConClusions: Even well-established measures for AD 
patients should have their content validity evaluated prior to their use in pAD or MCI 
populations. In this study, we found that the PDQ and RUD –Lite needed modifications 
to be more relevant in early stage patients.
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objeCtives: Timeline and budget considerations for the linguistic validation of 
Clinical Outcome Assessments (COAs) can vary substantially depending on patient 
population requirements and target locales. Rare diagnoses and/or small popula-
tions of native speakers of a language can lead to a small pool of eligible patients 
for cognitive debriefing respondents. This review highlights considerations neces-
sary to promote successful linguistic validation projects and mitigate the potential 
impact of small patient populations that, in turn, can affect study timelines as a 
whole. Methods: To assess possible steps to take during study planning and the 
linguistic validation process, a literature review and examination of past linguistic 
validation projects were completed. This focused on trials in which a small patient 
population limited the number of eligible cognitive interviewing respondents, and 
the issues and solutions associated with each project. Results: In order to meet 
timeline and budget requirements, it is crucial that sufficient steps are taken to 
ensure cognitive interviewing populations are fully evaluated during a trial’s plan-
ning stages. Solutions for helping achieve this include: 1) Identification and possible 
inclusion of broader patient populations with conditions with similar symptoms; 2) 
Extended timeline consideration for rare diseases or small native-speaking popula-
tions at study start; 3) Selection of more general COAs (e.g. not specific to the diag-
nosis in the case of rare conditions) so cognitive interviewing may be performed on 
healthy respondents or a broader group of patients. ConClusions: When choosing 
COAs for global use, an analysis of the intended patient population – including 
prevalence rates of the condition and size of the native-speaking population – is 
recommended in order to integrate projected linguistic validation timelines into 
the overall study plan. It is also recommended that study teams discuss this with 
their language services team for guidance on timelines and assistance in planning 
to ensure targeted study milestones are met.
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ity to understand and complete six consent tasks. They also provided information 
about themselves (maternal education, willingness to enroll child in a clinical trial) 
and their child (age, autism status, thinking/reasoning ability, gender). Results: 
Factor analysis confirmed that the six items comprise a single factor. However, we 
found a clear hierarchy of difficulty; the least difficult tasks were “understands that 
this medication is different from his/her regular treatment” and “realizes that he/
she can choose to participate in the study or withdraw at any time.” The most dif-
ficult were “can make a decision about study participation” and “understands and 
weighs potential benefits and risks of participating in the study.” Although 29% of 
parents reported that their son was not at all capable of participating, the remainder 
exhibited a range of decisional skills. Factors associated with this variability include 
gender, autism, cognitive ability, age, and parents’ willingness to enroll their child 
in clinical trials. ConClusions: Parents rate many individuals with FXS as able to 
participate in the consent process, but they will likely need support to maximize 
effective participation. We conclude with a brief review of strategies to support more 
inclusive participation in the consent process for people with ID.
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objeCtives: Primary objective of the Percepolis study was to look at patient’s percep-
tion regarding their Erythropoiesis Stimulating Agents (ESA) treatment of anemia in 
chronic kidney disease. Many discussions arose at the set-up of the study regarding 
the best collection method of PROs as target population was old. The following fac-
tors helped to make a decision towards ePRO: - Clinical data were collected using 
an eCRF and previous experience of studies using PROs showed it was difficult to 
mix method of collecting data, - PRO was the primary endpoint of this study and 
needed to be carefully monitored, - Most elderly people use new technologies (cellular 
phone, PC), - Twenty questionnaires needed to be equally distributed. Methods: 
This is a 6-month multicenter prospective Non-Interventional Study (NIS). Patients 
had to complete questionnaires at baseline and around 6-month in order to analyze 
the importance they gave to their ESA treatment characteristics. Technology used 
was the Tablet PC Samsung Galaxy Tab and specific interface was developed on the 
Operating System (O.S.) Android to maximize ease of use of the device for patients 
and investigators. For example, patients only had to select an answer on the screen 
to display the next question using the tactile functionnalities of the device. When 
connecting to the electronic data capture system, O.S. was detected in order to fit the 
screen’s display of the HTML pages. Results: A total of 789 patients were included, 
93% patients answered at least one questionnaire at baseline, 87% after 6 months 
of treatment. Mean age of the study population was 73 years old (± 13 years). Most 
PROs (95%) were answered using the Tablet PC. ConClusions: ePROs can be used in 
elderly population as long as tools are adequately developed to simplify use of devices. 
ePROs also allowed following online study recruitment and questionnaires data entry.
PRM164
how bURdensoMe is coMPletion oF electRonic Patient-RePoRted 
oUtcoMes (ePRo)? iteM coMPletion tiMes and QUalitative evidence 
FRoM stUdies in FoUR diFFeRent health conditions
Arbuckle R.1, Tolley C.1, Burbridge C.2
1Adelphi Values, Bollington, UK, 2Pfizer Ltd., Surrey, UK
objeCtives: The patient burden of completing large numbers of patient-reported 
outcome (PRO) items is often a concern; particularly when PROs must be completed 
daily, or at multiple timepoints over long studies. However, as ePRO and mPRO 
(technology that utilizes patients’ personal tablets and smartphones) methods 
advance, PRO completion becomes quicker and easier. How long does it actually 
take patients to complete ePROs? How burdensome do patients find ePRO comple-
tion? Methods: ePRO allows collection of the time taken to complete a set of PRO 
items. We summarise data from four qualitative studies across a range of health 
conditions (fibromyalgia, a women’s health condition, pediatric constipation and 
pediatric irritable bowel syndrome). In all four studies, small samples of patients 
(n= 20-65) completed an ePRO diary daily for 5-9 days during pilot testing prior to 
cognitive debriefing. Completion times and missed days were collected. During 
the cognitive debriefing interviews patients were asked how burdensome the PRO 
completion was and if they had difficulty fitting it into their daily routine. Results: 
The PROs being developed had 15-35 items, but two included skip patterns, reducing 
the item burden. Average completion times ranged from 2.5-5.5 minutes per diary. 
For diaries without skip patterns, mean ‘per item’ completion times were calculated 
to range from 9.4-15.7 seconds. The majority of patients (93-100%) reported that the 
PRO was quick and easy to complete and not burdensome. Missed diary rates were 
consistently low with only 0-12% of patients missing more than one diary comple-
tion in the two studies where this information was collected. ConClusions: These 
data provide evidence that patients (including children) can complete ePRO diaries 
very quickly, don’t find this burdensome, and are happy to complete relatively large 
numbers of items daily. If ePROs are carefully designed, using skip-patterns and 
event driven items, completion burden can be reduced even further.
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objeCtives: The 4-item Morisky Medication Adherence Scale (MMAS-4) and the 
more recent 8-item version (MMAS-8) have been both validated, and their concur-
rent validity has been assessed among hypertensive patients, but the extent to 
which the two scales can be compared against one another has not been deter-
mined. The current analysis assessed whether adherence scores obtained with 
